Novel 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives, ligands of GABAA/benzodiazepine receptor complex
EXCLI Journal · 20.02.2023 · 22 · 250-262
DOI: 10.17179/excli2022-5639 ↗Kurz gefasst
Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 20.02.2023. Verfasst von Elham Rezaee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Agonists of Benzodiazepine (BZD) receptor are exhaustively used in the control of muscle spasms, seizure, anxiety, and insomnia. BZDs have some unwanted effects; therefore, the development of new BZD receptor agonists with better efficacy and fewer unwanted effects is one of the subjects of interest. In this study, based on the pharmacophore/receptor model of the BZD binding site of GABAA receptors, a series of new 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives (6a-f) were designed. Energy minima conformers of the designed compounds and diazepam were well matched in conformational analysis and showed proper interaction with the BZD-binding site of the GABAA receptor model (α1β2ϒ2) in docking studies. The designed compounds were synthesized in acceptable yield and evaluated for their in vitro affinity to the benzodiazepine receptor of rat brains by radioligand receptor binding assay. The results demonstrated that the affinities of most of the novel compounds were even higher than diazepam. The novel compound 6a with the best affinity in radioligand receptor binding assay (Ki=0.44 nM and IC50= 0.73±0.17 nM) had considerable hypnotic activity and weak anticonvulsant and anxiolytic effects with no negative effect on memory in animal models. Flumazenil as a selective benzodiazepine receptor antagonist was able to prevent hypnotic and anticonvulsant effects of 6a indicating the role of BZD receptors in these effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Premier Care Long Term Care Pharmacy, North Little Rock, Arkansas, USA.
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Rezaee, E., Ahmadi, F., Shabaninia, M., Khoramjouy, M., Azizi Farsani, Z., Shahhosseini, S., Tabatabai, S. A., & Faizi, M. (2023). Novel 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives, ligands of GABAA/benzodiazepine receptor complex. EXCLI Journal, 22, 250-262. https://doi.org/10.17179/excli2022-5639
Vancouver
Rezaee E, Ahmadi F, Shabaninia M, Khoramjouy M, Azizi Farsani Z, Shahhosseini S, et al. Novel 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives, ligands of GABAA/benzodiazepine receptor complex. EXCLI Journal. 2023;22:250-262. doi:10.17179/excli2022-5639
BibTeX
@article{Rezaee2023,
author = {Rezaee, Elham and Ahmadi, Fatemeh and Shabaninia, Mahsa and Khoramjouy, Mona and Azizi Farsani, Zahra and Shahhosseini, Soraya and Tabatabai, Sayyed Abbas and Faizi, Mehrdad},
title = {Novel 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives, ligands of GABAA/benzodiazepine receptor complex},
journal = {EXCLI Journal},
year = {2023},
volume = {22},
pages = {250--262},
doi = {10.17179/excli2022-5639}
}
EUVIMED